Cargando…

Cell-Specific Aptamers as Emerging Therapeutics

Aptamers are short nucleic acids that bind to defined targets with high affinity and specificity. The first aptamers have been selected about two decades ago by an in vitro process named SELEX (systematic evolution of ligands by exponential enrichment). Since then, numerous aptamers with specificiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Cindy, Hahn, Ulrich, Rentmeister, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166764/
https://www.ncbi.nlm.nih.gov/pubmed/21904667
http://dx.doi.org/10.4061/2011/904750
_version_ 1782211183773745152
author Meyer, Cindy
Hahn, Ulrich
Rentmeister, Andrea
author_facet Meyer, Cindy
Hahn, Ulrich
Rentmeister, Andrea
author_sort Meyer, Cindy
collection PubMed
description Aptamers are short nucleic acids that bind to defined targets with high affinity and specificity. The first aptamers have been selected about two decades ago by an in vitro process named SELEX (systematic evolution of ligands by exponential enrichment). Since then, numerous aptamers with specificities for a variety of targets from small molecules to proteins or even whole cells have been selected. Their applications range from biosensing and diagnostics to therapy and target-oriented drug delivery. More recently, selections using complex targets such as live cells have become feasible. This paper summarizes progress in cell-SELEX techniques and highlights recent developments, particularly in the field of medically relevant aptamers with a focus on therapeutic and drug-delivery applications.
format Online
Article
Text
id pubmed-3166764
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-31667642011-09-08 Cell-Specific Aptamers as Emerging Therapeutics Meyer, Cindy Hahn, Ulrich Rentmeister, Andrea J Nucleic Acids Review Article Aptamers are short nucleic acids that bind to defined targets with high affinity and specificity. The first aptamers have been selected about two decades ago by an in vitro process named SELEX (systematic evolution of ligands by exponential enrichment). Since then, numerous aptamers with specificities for a variety of targets from small molecules to proteins or even whole cells have been selected. Their applications range from biosensing and diagnostics to therapy and target-oriented drug delivery. More recently, selections using complex targets such as live cells have become feasible. This paper summarizes progress in cell-SELEX techniques and highlights recent developments, particularly in the field of medically relevant aptamers with a focus on therapeutic and drug-delivery applications. SAGE-Hindawi Access to Research 2011 2011-08-28 /pmc/articles/PMC3166764/ /pubmed/21904667 http://dx.doi.org/10.4061/2011/904750 Text en Copyright © 2011 Cindy Meyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Meyer, Cindy
Hahn, Ulrich
Rentmeister, Andrea
Cell-Specific Aptamers as Emerging Therapeutics
title Cell-Specific Aptamers as Emerging Therapeutics
title_full Cell-Specific Aptamers as Emerging Therapeutics
title_fullStr Cell-Specific Aptamers as Emerging Therapeutics
title_full_unstemmed Cell-Specific Aptamers as Emerging Therapeutics
title_short Cell-Specific Aptamers as Emerging Therapeutics
title_sort cell-specific aptamers as emerging therapeutics
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166764/
https://www.ncbi.nlm.nih.gov/pubmed/21904667
http://dx.doi.org/10.4061/2011/904750
work_keys_str_mv AT meyercindy cellspecificaptamersasemergingtherapeutics
AT hahnulrich cellspecificaptamersasemergingtherapeutics
AT rentmeisterandrea cellspecificaptamersasemergingtherapeutics